argenx: Innovation Over Losses In Autoimmune Arena

Vesnaandjic/E+ via Getty Images Argenx Performance and Prospects Amid Market Challenges Argenx's (NASDAQ:ARGX) stock is down 22% since my last evaluation in October. Back then, I noted growing revenue opportunities for the company's lead asset, Vyvgart. argenx, a biotechnology developer based in Amsterdam, is a leader in the anti-FcRn market, which is expected to grow to over $10 billion. Last quarter (Q4), argenx reported $374 million in global net product revenues (Vyvgart and Vyvgart Hytrulo) and $41 ...